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Stereotactic Core-Needle Biopsy of
Non-Mass Calcifications: Outcome and
Accuracy at Long-Term Follow-Up
Objective: To determine, by means of long-term follow-up evaluation, the out-
come and accuracy of stereotactic core-needle biopsy (SCNB) of non-mass calci-
fications observed at mammography, and to analyze the factors contributing to
false-negative findings.
Materials and Methods: Using a 14-gauge needle, SCNB was performed in
cases involving 271 non-mass calcified lesions observed at mammography in
267 patients aged 23 72 (mean, 47) years. We compared the SCNB results with
those of long-term follow-up which included surgery, mammography performed
for at least six months, and reference to Korean Cancer Registry listings. We
investigated the retrieval rate for calcifications observed at specimen mammogra-
phy and histologic evaluation, and determined the incidence rate of cancer, sen-
sitivity, and the underestimation rate for SCNB. False-negative cases were evalu-
ated in terms of their mammographic findings, the effect of the operators’ experi-
ence, and the retrieval rate for calcifications.
Results: For specimen mammography and histologic evaluation of SCNB, the
retrieval rate for calcifications was, respectively, 84% and 77%. At SCNB, 54 of
271 lesions (19.9%) were malignant [carcinoma in situ, 45/54 (83%)], 16 were
borderline, and 201 were benign. SCNB showed that the incidence of cancer was
5.0% (6/120) in the benign mammographic category and 31.8% (48/151) in the
malignant category. The findings revealed by immediate surgery and by long-
term follow-up showed, respectively, that the sensitivity of SCNB was 90% and
82%. For borderline lesions, the underestimation rate was 10%. For false-nega-
tive cases, which were more frequent among the first ten cases we studied (p =
0.01), the most frequent mammographic finding was clustered amorphous calci-
fications. For true-negative and false-negative cases, the retrieval rate for calci-
fications was similar at specimen mammography (83% and 67%, respectively; p
= 0.14) and histologic evaluation (79% and 75%, respectively; p = 0.47).
Conclusion: In this study group, most diagnosed cancers were in-situ lesions,
and long-term follow-up showed that the sensitivity of SCNB was 82%. False-
negative findings were frequent during the operators’ learning period.
ince stereotactic breast biopsy was first described in 1990 (1), the proce-
dure  though less common in Korea  has been widely used in western
countries as an adjunct to breast radiology. The continually increasing
number of women undergoing annual mammographic screening has led to an increase
in the number of (mostly calcified) nonpalpable abnormalities identified (2).
Calcification has been shown to be a component in up to 50% of malignant lesions (3),
and in 84% of ductal carcinomas in situ (DCIS), the presence of calcification has been
demonstrated by mammography (4). Although morphological analysis can provide
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e-mail: bkhan@smc.samsung.co.kr Sguidelines for the management of these patients, many cal-
cifications are indeterminate, and without the use of core
biopsy, unnecessary surgical biopsy for benign lesions or
the delayed diagnosis of malignant lesions is therefore like-
ly.
In Korea, because of the relatively high expense in-
volved and a poor understanding of the need for stereotac-
tic equipment, ultrasonography (US)-guided core biopsy is
more popular. It should be borne in mind, we believe, that
for this procedure, the proper indication is a sonographical-
ly visible mass, and the use of US-guided biopsy for calci-
fications is limited. According to most published reports,
however, the targets for core biopsy are all types of non-
palpable mammographic abnormalities, including a mass,
calcifications, or a calcified mass (5 7). The reported con-
cordance rate for surgical and stereotactic biopsy is 87
96% (5).
In this article, we describe our findings, including those
determined during long-term follow-up, regarding the out-
come and accuracy of stereotactic core-needle biopsy (SC-
NB) of non-mass calcifications observed at mammography.
We also analyze the factors contributing to false-negative
findings.
MATERIALS AND METHODS
Between April 1997 and March 2002, 284 SCNBs of
nonpalpable mammographic calcifications were attempted
at our institution. Thirteen of these (5%) were aborted
[calcifications too faint or diffuse (n=8); breast too thin
(n=3); calcifications too posterior (n=2)], and 267 consec-
utive patients aged 23 72 (mean, 47) years thus under-
went 271 SCNBs. Our preference was to use US-guided
core biopsy for all nonpalpable breast lesions (including
calcifications) requiring biopsy, and SCNB only where US-
guidance was regarded as too difficult after evaluating the
imaging findings. Thus, during the above period, SCNB
was used in only 20 cases involving a suspicious density or
mass. Unless calcifications were within a mammographical-
ly fatty area, the usual purpose of pre-SCNB US was to lo-
cate a calcified mass.
Prior to commencing the procedure, the radiologists used
the Breast Imaging Reporting and Data System (BI-RADS)
to determine a mammographic assessment category of be-
tween 2 and 5.
SCNB was performed using a prone table stereotactic
mammographic unit (StereoGuide DSM; LoRad Medical
Systems, Danbury, Conn., U.S.A.), an automated gun
(Biopty Gun; Bard, Covington, Ga., U.S.A.), and a 14-
gauge needle (Biopty-Cut; Bard, Covington, Ga., U.S.A.).
The median number of core specimens obtained was seven
(range, five to 20). A long-excursion (2.3-cm throw) needle
was used in the majority of cases, but in eight, the short-
excursion type (1.2-cm throw) was used because of limited
breast thickness. After adequate core tissues were ob-
tained, the specimens were placed on a saline-moistured
filter paper and radiographed without compression on a
digital receptor of stereotactic equipment at 24 28 kVp
and 8 mAs. If no calcified particles were visible, additional
specimens were obtained until calcifications were identi-
fied or until further sampling was difficult due to either re-
current failure to acquire adequate tissue, or a patient’s in-
tolerance (8). All studies involved one of two radiologists
(B-K.H. or Y.H.C.).
If SCNB detected malignancy, a borderline lesion, or a
nonspecific benign lesion with definite radiologic-patholog-
ic discordance, needle localization-excision was performed.
Borderline lesions were those in which the pathologic find-
ings indicated a high possibility of carcinoma, and included
atypical ductal hyperplasia (ADH) and mucocele-like le-
sions (MLL). Where calcifications were mammographically
assesed as benign (B1-RADS 2 or 3) and the histologic
specimen was benign, close follow-up was recommended,
and rebiopsy was not routinely performed even though the
histologic specimen did not contain calcifications. A patient
with a benign SCNB diagnosis  even where this showed
radiologic-pathologic concordance  was advised to un-
dergo mammographic follow-up, but needle localization-
excision was performed if the patient wanted the lesions
removed, or they had progressed.
The pathologic results of SCNB and surgical biopsy were
analyzed and compared with the mammographic category.
Surgical biopsy was performed in 101 cases, and follow-up
mammograms obtained 6 48 (mean, 16) months later
were available in 98. The Korean Cancer Registry provid-
ed additional data regarding the development of cancer
among our study population. The incidence rate of cancer,
sensitivity, and underestimation rate for SCNB were inves-
tigated. The retrieval rates for calcification observed at
specimen mammography and histologic evaluation were
examined, and the respective numbers of true-negative
and false-negative cases were compared. The latter were
evaluated with regard to their mammographic findings, the
effect of the operators’ experience, and the retrieval rate
for calcifications observed at specimen mammography, and
histologic evaluation. Statistical significance was deter-
mined using Fisher’s exact test.
An SCNB diagnosis of a borderline lesion with a surgical
diagnosis of in-situ or invasive carcinoma, or an SCNB diag-
nosis of in-situ carcinoma with a surgical diagnosis of inva-
sive carcinoma was regarded as a “histologic underesti-
mate.” An SCNB finding of benignancy or insufficiency
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at surgery indicated malignancy, irrespective of the interval
between surgical biopsy and SCNB. An SCNB diagnosis of
carcinoma was considered “true-positive,” with or without
confirmation by means of excisional biopsy.
RESULTS
Calcifications were observed in 228 of 271 cases (84%)
at specimen mammography and 210 of 271 cases (77%) at
histologic evaluation of core tissue.
Table 1 compares the pathologic results of SCNB with
mammographic category. At SCNB, 54 of 271 lesions
(19.9%) were malignant, 16 (5.9%) were borderline
(ADH, 10; MLL, 6), and 195 (72.0%) were benign; in six
cases (2.2%), adequate pathologic diagnosis was impossi-
ble. Of 54 malignant lesions, 45 (83%) were carcinomas in-
situ.
Table 2 shows the incidence rate of cancer as a function
of mammographic category, comparing the findings of SC-
NB with the final diagnosis in 101 surgical biopsies and
170 cases involving follow-up. (In 98 of these, mammo-
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Table 1. Comparison of the Pathologic Results of SCNB and
the Mammographic Category of 271 Non-mass
Calcified Lesions
Mammographic Category
SCNB
Benign Malignant 
Total
Carcinoma 6 (5.0) 48 (31.8) 54 (19.9)
IDC 02 07 09
DCIS 044 0 4 4
LCIS 00 01 01
Borderline lesions 1 (0.8) 15 (9.9) 16 (5.9)
ADH 001 0 1 0
MLL 01 05 06
Benign lesions 108 (90.0) 87 (57.6) 195 (72.0)
Fibrocystic change 47 36 83
Fibrosis 39 33 72
Fibroadenoma 02 05 07
Papillary lesion 00 02 02
Others 20 11 31
Inadequate findings 5 (4.2) 1 (0.7) 6 (2.2)
Total 120 (100) 151 (100) 271 (100)
Note. Numbers in parentheses represent percentages.
IDC=invasive ductal cancer, DCIS=ductal carcinoma in-situ,
LCIS=lobular carcinoma in-situ, ADH=atypical ductal hyperplasia,
MLL=mucocele-like lesion
BI-RADS category 2 or 3,  BI-RADS category 4 or 5
Fig. 1. A 46-year-old woman with calcifications detected at screening mammography.
A. Routine mammogram obtained at the time of SCNB depicts multiple amorphous round calcifications in a 7-mm cluster, but no mass
(arrow). Ultrasonography also failed to identify a mass associated with these calcifications (not shown here). Mammography of the SC-
NB core tissue specimen revealed a calcified particle, and the histologic diagnosis was fibrocystic change, with calcifications.
B. Mammogram obtained 13 months after SCNB, at which time the patient reported the presence of a lump, reveals a 2-cm-sized, irreg-
ular-shaped mass (arrowheads) at the same site, where a similar number of calcifications were present (arrows). Ultrasonography visual-
ized two 2-cm sized masses above and below the nipple (not shown here). A modified radical mastectomy revealed the presence of a 4-
cm-sized invasive ductal carcinoma, and single axillary lymph node metastasis.
AB
Table 2. The Incidence Rate of Cancer as a Function of
Mammographic Category: Comparison between
SCNB Findings and Final Diagnosis, Including the
Surgical and Follow-up Results
Incidence Rate Mammographic Category
of Cancer Benign Malignant
Total
SCNB 5.0% (6/120) 31.8% (48/151) 19.9% (54/271)
Final Diagnosis08.3% (10/120) 37.7% (57/151) 24.7% (67/271)
BI-RADS category 2 or 3,  BI-RADS category 4 or 5graphic follow-up was longer than 6 months; in 72, the pa-
tients were lost to follow-up but were matched with data
stored at the Korean Cancer Registry.) In the group in
which mammographic assessment was benign (BI-RADS 2
or 3), the incidence of cancer was 5.0% (6/120) for SCNB
and 8.3% (10/120) for surgical biopsy, while for the BI-
RADS 3 group, the corresponding figures were 5.5%
(6/109) and 9.2% (10/109). In the BI-RADS 4 or 5 group
(malignant assessment), the respective incidences were
31.8% (48/151) and 37.7% (57/151).
Table 3 displays the results of long-term follow-up, in-
cluding a comparison of the pathologic results obtained at
SCNB and surgical biopsy. Twelve additional cancers
(false-negative cases) were found at immediate (n=6) or
delayed (n=6) surgical biopsy among 211 cases with a be-
nign or inadequate histologic result at SCNB, and one
more cancer (a histologically underestimated case) was
found among 16 cases in which SCNB revealed borderline
histologic findings. Thus, among the 271 lesions, 67 can-
cers (24.7%) were finally diagnosed. Six false-negative cas-
es, all of which were shown to be DCIS, were disclosed at
immediate surgical biopsy performed due to radiologic-SC-
NB pathologic discrepancy. In one such case, although the
mammographic category was BI-RADS 3, needle localiza-
tion-surgical biopsy and SCNB were both performed on
the same day, since this was our first SCNB case. The im-
mediate surgical biopsy result indicated an SCNB sensitivi-
ty of 90% (55/61). Between six and 48 (mean, 19.8; medi-
an, 15.5) months after SCNBs, six further false-negative
cases were disclosed at delayed surgical biopsy and by ex-
amining the listings maintained at the Korean Cancer
Registry. On the basis of the long-term follow-up result,
the final sensitivity of SCNB was thus found to be 82%
(55/67). At the time of final diagnosis, four of six lesions
were nonpalpable and the axillary lymph node was not in-
volved, but two were palpable and associated with axillary
lymph node metastasis. The pathologic diagnosis was inva-
sive ductal cancer in four cases, mucinous cancer with
DCIS in one, and DCIS in one. One false-negative case in
which the final diagnosis was still DCIS was diagnosed 48
months after SCNB. Two others were diagnosed as cancers
at other hospitals 18 and 25 months later, respectively, and
information regarding the pathologic diagnosis, radiologic
findings, and location of the cancers was obtained from
those hospitals and the Korean Cancer Registry.
The underestimation rate of surgically excised borderline
lesions and carcinomas in-situ was 10.0% (1/10) and
12.5% (5/40), respectively. One MLL was upgraded to a
DCIS; no ADH was upgraded to a carcinoma, but five of
six were downgraded at excision to usual ductal hyperpla-
sia or fibrocystic change. Two ADH patients were lost to
follow-up and their names did not appear in the records at
the Korean Cancer Registry.
Mammographically, false-negative cases appeared as
clustered, multiple, faint, amorphous calcifications (Figs. 1
A, B). False-negative cases accounted for 12 of the total of
67 cancers (18%) [4 of 8 (50%) of those diagnosed during
the first year, and 3 of 4 (75%) of those among the first ten
cases (a proportion significantly higher than among the re-
maining 261 cases) (p = 0.01)]. If the period during which
the first ten cases were diagnosed is excluded, being re-
garded as a learning period, the false-negative rate decreas-
es from 18% (12/67) to 14% (9/54) and the sensitivity of
SCNB increases from 82% (55/67) to 86% (54/63). For
true-negative and false-negative cases, the retrieval rate for
calcifications was not significantly different between speci-
men mammography [170/204 (83%) versus 8/12 (67%) (p
= 0.14)] and histologic evaluation [162/204 (79%) versus
Han et al.
220 Korean J Radiol 4(4), December 2003
Table 3. Long-Term Follow-Up Data, Including a Comparison of the Pathologic Results Obtained at SCNB and Surgical Biopsy
Surgical Biopsy
SCNB
Total Follow-Up Loss Sub-total
Carcinoma
ADH Benign Lesions
IDC DCIS Mucinous Cancer
IDC 009 00 04 05 05 000 0 00
DCIS 044 00 053 9043 5 0 0 00
LCIS 001 00 00 01 01 000 0 00
ADH 010 02 02 06 00 000 1 05
MLL 006 01 01 04 00 010 0 03
Benign lesions 195 94 57 44 03 071 2 3 1
Inadequate findings 006 01 03 02 01 000 0 01
Total 271 (100) 98 (36) 72 (27) 101 (37) 14 43 1 3 40
Note. Numbers in parentheses represent percentages.
IDC=invasive ductal cancer, DCIS=ductal carcinoma in situ, LCIS=lobular carcinoma in situ, ADH=atypical ductal hyperplasia, MLL=mucocele-like lesion
The follow-up interval was 6 48 (mean, 16; median, 12) months.9/12 (75%) (p = 0.47)].
DISCUSSION
In the past, needle localization-excision was considered
the best technique for the accurate diagnosis of nonpalpa-
ble breast lesions detected during screening. The problems
associated with diagnostic surgical biopsy include, howev-
er, a large scar, the general risks associated with open
surgery (particularly where general anesthesia and hospi-
talization are involved), and a low positive biopsy rate (9).
In Korea, US-guided core needle biopsy has an estab-
lished role in the diagnosis of nonpalpable breast lesions,
but for SCNB, this is not so. Many nodules or masses ob-
served at US have, therefore, been biopsied under US-
guidance, but those not seen at US, such as non-mass calci-
fications, have been neglected, only followed-up, or oper-
ated on in two steps, diagnostic and therapeutic. If calci-
fications are identified at US, US-guided core biopsy may,
of course, be possible; its advantages over SCNB include a
shorter procedure time and less patient discomfort, particu-
larly in Asian women with small breasts, in whom position-
ing and compression during stereotactic biopsy are diffi-
cult. However, the reported success rate of pre-SCNB US
in identifying calcifications is 35.8% (10), and although the
success rate of US-guided core biopsy of calcifications iden-
tifiable at US has been reported to be up to 100% (11), the
difficulty of accurately targeting the tiny specular reflec-
tors, as well as interference in the multipass technique by
introduced air, is well recognized. Accordingly, the biopsy
of non-mass calcifications requires the use of stereotactic
equipment.
The incidence rate of cancer (i.e. the positive biopsy rate)
determined using an image-guided core needle, for non-
palpable lesions, varies according to the target population,
whether or not probably-benign lesions are included. Most
reports suggest, however, that for nonpalpable lesions, the
rate is 13 to 37% (12 14). According to the findings of a
multi-institutional study undertaken by Parker et al. (12),
the incidence rate of cancer for stereotactic and US-guided
biopsy was similar (15% vs 17%), but for DCIS alone, the
rate was much higher for stereotactic-guided biopsy
(31.4% vs 6.9%). A domestic report on US-guided core
needle biopsy showed that DCIS accounted for 10.9% of
all cancers (13). In Korea, where stereotactic equipment is
not generally used, a diagnosis of DCIS still depends on
needle localization-excision or close observation until a
DCIS becomes larger or progresses to an invasive cancer.
DCIS is a precursor of invasive breast carcinoma, and gen-
erally becomes invasive within three to five years, particu-
larly at high grades, though a low-grade DCIS can take up
to 20 years to progress to an invasive cancer (15). The nat-
ural course of a DCIS is still unknown, but because the
purpose of screening is to detect and remove a cancer dur-
ing its early stage, effort has focused on increasing the de-
tection rate during the DCIS phase. We suggest, therefore,
that the use of SCNB in Korea should be further encour-
aged. In this study, the histologic findings of SCNB showed
that DCIS accounted for 83% of all cancers.
Our results showed that among lesions whose mammo-
graphic category was benign, cancer was diagnosed at SC-
NB in 5.0% of cases (6/120). If these lesions had been ne-
glected, six cases of cancer [DCIS (n=4) and invasive can-
cer (n=2)] could have been missed. In this group, follow-
up revealed four more cancers, of which three (including
two that progressively became invasive) were detected at
least nine months after SCNB. Sickles (16) suggested that
among category- 3 lesions (“probably benign”) requiring
follow-up every six months for two or three years, the inci-
dence of cancer is  2%. Numerous articles have shown
that the positive core biopsy rate of BI-RADS 3 was 3-
13% (9, 17); the 5% detection rate for BI-RADS 3 noted
in this study does not reflect the cancer rate for all BI-
RADS 3 lesions, for which mammographic follow-up was
routinely recommended. Some patients, however, such as
those with a past history of breast cancer, a personal pref-
erence, or about whom a clinician was concerned, under-
went core biopsy. It is not intended that the findings of this
study should encourage tissue sampling of all BI-RADS 3
lesions, but the inclusion of many such cases reflects the re-
cent trend of histologically confirming an apparently be-
nign lesion in order to dispel a patient’s anxiety and that of
their clinicians (and perhaps radiologists). Another concern
relating to the follow-up of BI-RADS 3 lesions is that a pa-
tient might not follow the instructions received. In fact,
62/157 (39.5%) of our patients whose SCNB results were
benign and three with borderline results (ADH or MLL),
and who were asked to return six months later, were lost
to follow-up. Among this former group, two additional in-
vasive cancers were discovered at other hospitals. In pa-
tients with BI-RADS 3 lesions, follow-up mammography
should, therefore, be strictly enforced.
Some surgeons have suggested that BI-RADS 4 lesions
should be surgically excised, though in our study group,
the positive biopsy rate for calcifications of this grade was
31.8% (48/151). Excluding the 39 surgically excised le-
sions for which discordance was strong, the use of SCNB
meant that for 64 of 151 BI-RADS 4 lesions, an unneces-
sary surgical biopsy was unequivocally avoided.
In this study, the sensitivity of SCNB, based on the re-
sults of immediate surgical biopsy and long-term follow-up
was, respectively, 90% (55/61) and 82% (55/67). As com-
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large core-needle-biopsy series (18), the false-negative rate
of 18% in our series was, we thought, too high. Since,
however, SCNB showed that the cancers in this study
group were mostly DCIS (45/54, 83%), and the target
mammographic findings were non-mass calcifications, this
level of accuracy is not lower than that noted in other re-
ports (12, 19). Brenner et al. (19) reported that the sensi-
tivity of core biopsy was 99% for invasive cancer and
67% for DCIS. In addition, its diagnostic accuracy was 98-
99% for masses and 87 91% for calcifications. In our
study, sensitivity was 82% overall, 79% for invasive can-
cer cases, and 85% for DCIS. The histologic results for the
five missed invasive cancers were , however, obtained at
surgical biopsy performed between 6 and 25 months after
SCNB. In these cases, the histologic diagnosis at the time of
SCNB could have been ADH or DCIS.
Although several published reports have suggested that
the diagnostic accuracy of SCNB and surgical excision is
similar (1, 7, 20, 21), many variables may determine that
of the former. These include the mammographic appear-
ance of the lesions (mass, calcified mass, or calcifications),
the number and volume of core biopsy samples, and pro-
gressive improvement in the performance of the radiolo-
gists involved. In eight cases, due to the limitation imposed
by the compressed thickness of the breast, we were obliged
to use short excursion needles, and in one of the patients
involved, immediate surgery indicated a false-negative
finding. A recent development, namely vacuum-assisted
percutaneous biopsy, which is able to obtain a larger vol-
ume of suspicious tissue after only one puncture, holds
much promise, particularly for determining the nature of
nonpalpable, US-nonvisible microcalcified lesions (9).
One of the most important factors contributing to the ac-
curacy of the procedures is improvement which occurs as
operators gain experience (19, 22). Earlier investigators
have suggested that for stereotactic breast biopsy, a learn-
ing curve exists, and have reported that significantly higher
technical success rates and lower false-negative rates were
achieved after the first five to 20 cases involving stereotac-
tic 14-gauge automated core biopsy (22).
The reported calcification retrieval rate at specimen
mammography has generally been 85 100% (22 24),
but, in this study, the rate was 84%. This slightly lower fig-
ure might be due to the larger population of probably be-
nign lesions, which were generally small clusters of indis-
tinct calcifications. An earlier study (24) noted that amor-
phous calcifications portended higher failure rates at
stereotactic biopsy, even with a vacuum-assisted device.
Although the usual radiographic settings for the imaging of
core specimens are 22 23 kVp and 7 20 mAs (23, 24),
we performed specimen mammography using the monitor
of a digital stereotactic machine set at 24 28 kVp and 8
mAs: at these settings, most calcifications were visible.
Because of the amorphous morphology encountered en-
countered, we were not always convinced of the presence
of calcifications, and under such circumstances and in order
to verify the accuracy of targeting, searched for these in
the histologic specimens obtained. However, study of the
histologic correlation of core biopsy specimens suggested
that if calcification is not visible on a core biopsy radi-
ograph, any microscopic calcification observed in histologic
sections would not represent radiologic calcification (be-
cause microscopic tissue calcification would be smaller
than that resolved at radiography) (25). Among 16 cases in
which we ensured targeting accuracy by confirming the
presence of calcification in a histologic specimen, two were
found to be false-negative. Our histologic retrieval rate for
calcifications was lower than the radiographic retrieval
rate, and radiographically visible calcium was not evident
at pathologic analysis in 25 of 228 cases (11%). For this,
there are at least three possible explanations: calcium may
be lost during tissue preparation, or can be dislodged from
the tissue by the blade; calcifications made up of calcium
oxalate crystals are difficult to visualize in histologic sec-
tions; tissue may be incompletely sectioned (23). Thus, if
radiographically visible calcifications in core tissues are not
identified in histologic sections, and the histologic diagnosis
is benign, it is essential to establish the presence of calcium
oxalate crystals by using a polarized microscope or to
search for histologically visible calcifications by obtaining
deeper sections. In this way, a false-negative diagnosis can
be avoided. In a paraffin block, a histologically diagnostic
area may be deeper (25). Although we did not obtain addi-
tional deeper sections in false-negative cases, calcification
was was observed in one such case on a core specimen ra-
diograph but not histologically, and invasive ductal cancer
was diagnosed 18 months later. In our study, both mam-
mographic and histologic retrieval rates for calcifications
showed no significant difference between true-negative
and false-negative cases, a finding which may reflect the in-
adequate amount of specimen obtained at spring-loaded
automated gun biopsy. This group consisted predominantly
of lesions seen as non-mass calcifications at mammogra-
phy; histologic examination showed that most diagnosed
cancers were DCIS, but this may reflect the difficulty of di-
agnosing ADH using only a limited amount of core tissue.
The low incidence rate of ADH (3.6%) and the absence of
histologic underestimation of ADH diagnosed at SCNB
suggest this possibility.
Since false-negative findings were concentrated among
the first ten cases investigated, we suggest that cases diag-
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followed up or further investigated by means of surgical
biopsy.
In conclusion, although stereotactic biopsy can be reli-
ably employed for the evaluation of calcifications observed
at mammography, long-term follow-up showed that when
the predominant mammographic finding was non-mass cal-
cifications and the most commonly diagnosed cancer was
DCIS, the sensitivity of SCNB was 82%. False-negative
findings were frequent during the operators’ learning peri-
od.
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